SEQUENCE-THERAPY AND INTERVAL THERAPY IN METASTATIC BREAST-CANCER WITH TAMOXIFEN AND MPA

Citation
E. Merkle et al., SEQUENCE-THERAPY AND INTERVAL THERAPY IN METASTATIC BREAST-CANCER WITH TAMOXIFEN AND MPA, Tumordiagnostik & Therapie, 15(3), 1994, pp. 104-108
Citations number
11
Categorie Soggetti
Oncology
Journal title
ISSN journal
0722219X
Volume
15
Issue
3
Year of publication
1994
Pages
104 - 108
Database
ISI
SICI code
0722-219X(1994)15:3<104:SAITIM>2.0.ZU;2-R
Abstract
In a prospective randomized study at the Department of Obstetrics and Gynaecology, University of Erlangen-Nuremberg, 86 patients with metast atic breast cancer and positive or unknown steroid hormone receptor st atus were refered to different hormone therapy schemes. One group of p atients (N = 44) received a sequence therapy with 30 mg of Tamoxifen d aily. In case fo relaps after original response the therapy was change d to MPA. The second group of patients (N = 42) received 30 mg/die Tam oxifen for 4 weeks. After a wash out period of 4 weeks, during which t he patients had no medication, a therapy with 1000 mg/die MPA followed . After a therapeutic pause of one week the scheme was started again. Both therapy schemes showed no significant difference concerning the r esponse rate (86 % in the sequence therapy - and 79 % in the interval therapy group). With regard to the response rate the interval therapy compared with the sequence therapy showed an advantage with respect to the lower absolute dosage used in these patients. Concerning the resp onse duration the sequence therapy was significantly superior to the i nterval therapy (32 versus 21 months response duration). Particularly remarkable is the difference in patients with complete remission, whic h had a median response duration of 47 months in the sequence therapy group compared with only 24 months in the interval therapy group. It s hould be noticed, that sequence therapy patients suffered further recu rrence before the therapeutic change from Tamoxifen to MPA. In contras t to this the response duration of the interval therapy refers to a si ngle hormone therapy with Tamoxifen and MPA alternately, without a cha nge of therapy due to a recurrence. Side-effects were minimal in both therapeutic schemes. Inspite of similar response rates the sequence th erapy with its longer response duration seems to be superior ot the in terval therapy, also with respect to the easier intake mode.